Weekly round up from Life Sciences Industry.
WNDM Medical acquires remaining 50% interest in Cellerat, from Catalyst Group
In exchange of 50% stake, WNDM issued 1,136,815 shares of its newly created Series F convertible preferred stock.
Following the closing of this transaction, Ron Nixon, Founder and Managing Partner of CGI, was elected to WNDM’s board.
Date: March 25, 2019
Send us an email, we will get in touch with you.
Source: Seeking Alpha
Sign up for DistilINFO e-Newsletters.
ERT and Bioclinica to Merge, Creating a Global Leader in Clinical Trial Endpoint Technology
Golden Gate Capital Invests in Ensemble Health Partners
Cybersecurity: Managing Risk in the COVID-19 Era
CARLSMED and Precisive Surgical Announce Merger
$15.7 Billion Eclinical Solutions Market Insights, 2020-2027: Focus on ECOA, EDC and CDMS
Will FDA’s new guidance boost medical device cybersecurity?
CVR Medical Agrees Proposed Acquisition of CVR Global
Enterprise Therapeutics’ First-in-class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired By Roche